Dr. Pass Discusses Resistance in Mesothelioma

Harvey I. Pass, MD
Published: Tuesday, Jul 29, 2014

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses treatment resistance in mesothelioma.

Researchers are trying to determine the difference between cells that are resistant to mesothelioma treatment and those that are not. Only about 4% of mesothelioma cells have unique properties that allow them to survive treatment with pemetrexed, stress conditions, or radiation therapy.

When the majority of mesothelioma tumor cells are killed, these unique cells will not respond — they will stay behind and repopulate the tumor, Pass says.

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses treatment resistance in mesothelioma.

Researchers are trying to determine the difference between cells that are resistant to mesothelioma treatment and those that are not. Only about 4% of mesothelioma cells have unique properties that allow them to survive treatment with pemetrexed, stress conditions, or radiation therapy.

When the majority of mesothelioma tumor cells are killed, these unique cells will not respond — they will stay behind and repopulate the tumor, Pass says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x